This study investigates the effectiveness of China’s Urgently Needed Overseas Drug (UNOD) policy, which aims to expedite access to innovative drugs for patients with unmet medical needs. Analyzing data from 2012 to 2019, the research reveals that the UNOD designation did not significantly reduce launch delays for new drugs compared to the United States. This finding suggests a potential overlap in benefits with other existing policies, undermining the intended prioritization of UNOD drugs.

This study highlights China's rapid development in pharmacoeconomics over two decades, driven by policy reforms, centralized drug procurement, and innovative pricing strategies. Despite progress, gaps remain in adopting global practices like real-world evidence and AI applications. China's drug price negotiations achieved a 60% average reduction, improving medication accessibility while balancing innovation and affordability.

Few tourism enterprises make net positive contributions to conservation, and “nature positive” terms are being used for “marketing greenwash, to delay and avoid environmental fees and regulations, and to lobby for land grabs in public protected areas”. 

Professor Ralf Buckley suggests Australia has adopted “nature positive” political terminology, but in practice has failed to implement past promises to establish a new independent Environment Protection Agency.